Conference Report

2006 International HIV Drug Resistance Workshop

Source: CCO Independent Conference Coverage of the 2006 International HIV Drug Resistance Workshop*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

2006 International HIV Drug Resistance Workshop

Faculty:
Daniel R. Kuritzkes, MD Jonathan M. Schapiro, MD

CME CREDIT INFORMATION

Release Date: 09/08/06

Expiration Date: 09/07/07

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Recount data on the occurrence of transmission of drug-resistant HIV
Describe new data on the prevalence and clinical impact of antiretroviral resistance mutations
List mutations associated with resistance to antiretroviral agents

Topics covered include:

Introduction
Impact of Primary Resistance on Virologic Response to HAART
Methamphetamine Use and Infection With Resistant HIV
Class Resistance After NNRTI Failure
Resistance and Progression After First-Line Failure
Resistance to Lopinavir/Ritonavir Monotherapy
Resistance After Stopping an NNRTI
Waning Rates of Triple-Class Resistance
RNase H Mutations and Resistance to NRTIs
Clinical Relevance of Hypersusceptibility to NNRTIs
Resistance to Tenofovir After Didanosine or Abacavir
Etravirine Activity Against K103N and Y181C
Predicting Response to Darunavir
Comparing Susceptibility Cutoffs for Tipranavir and Other PIs
CD4+ Cell Count Response Sustained After Enfuvirtide Failure
Exploring Viral Coreceptor Tropism
Difficulties in Understanding Reduced Response to CCR5 Antagonists
What to Watch for in CCR5 Antagonist Trials
Key Clinical Take-Home Lessons

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.